Literature DB >> 16020958

Alterations of rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma.

Shilpi Soni1, Jatinder Kaur, Anupam Kumar, Nitin Chakravarti, Meera Mathur, Sudhir Bahadur, Nootan Kumar Shukla, Suryanaryana V S Deo, Ranju Ralhan.   

Abstract

OBJECTIVE: This study was designed to test the hypothesis that alterations in expression of G1/S modulators cyclin D1, p16 and pRb occur in patients with oral epithelial dysplasia, considered to be at increased risk for malignant transformation. In addition, the analysis of expression of all three markers in the same set of oral cancer patients would provide a unique opportunity to determine whether these alterations have cooperative or synergistic effects on oral cancer development and prognosis. PATIENTS AND METHODS: A prospective study was undertaken to carry out immunohistochemical analysis of cyclin D1, p16 and pRb proteins in serial paraffin-embedded tissue sections of 220 oral squamous cell carcinomas (OSCCs), 90 potentially malignant lesions (52 oral hyperplastic lesions, 38 dysplasias) and 81 matched histologically normal oral tissues and correlated them with clinicopathological parameters. Ninety-eight OSCC patients were followed up for a maximum period of 94 months with overall median survival of 21 months.
RESULTS: Seventy-five of 90 (83%) potentially malignant lesions and 198 of 220 (90%) OSCCs showed altered expression of at least one of the proteins in the pRb pathway, while 10 of 90 (11%) patients with potentially malignant lesions and 40 (18%) of 220 OSCC patients showed all three alterations. Loss of p16 was the earliest event in oral tumorigenesis. In a multivariate model, loss of pRb was associated with transition from hyperplasia to dysplasia (OR = 3.727, p = 0.005). The transition of potentially malignant lesions to malignant stage was associated with pRb-/cyclin D1+ phenotype (OR = 2.294, p = 0.001) and p53+ phenotype (OR = 2.230, p = 0.002). Loss of pRb and accumulation of p53 (pRb-/p53+) phenotype was associated with histologic progression of the tumors and acquisition of invasive potential. Multivariate analysis using Cox's proportional hazards model revealed that pRb-/p53+ phenotype was the most significant adverse prognosticator for disease-free survival (hazards ratio, (HR) = 2.642, p = 0.004).
CONCLUSIONS: Deregulation of the p16/pRb/cyclin D1 pathway is an early event in acquisition of dysplasia, but deregulation of both pRb and p53 pathways is associated with malignant transformation and adverse prognosis in oral tumorigenesis. (c) 2005 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16020958     DOI: 10.1159/000086970

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  19 in total

1.  Smoking and drinking in relation to oral cancer and oral epithelial dysplasia.

Authors:  Douglas E Morse; Walter J Psoter; Deborah Cleveland; Donald Cohen; Mireseyed Mohit-Tabatabai; Diane L Kosis; Ellen Eisenberg
Journal:  Cancer Causes Control       Date:  2007-07-24       Impact factor: 2.506

2.  Cyclin D1 overexpression increases susceptibility to 4-nitroquinoline-1-oxide-induced dysplasia and neoplasia in murine squamous oral epithelium.

Authors:  Jonathan F Wilkey; Glenn Buchberger; Kirsten Saucier; Salony M Patel; Ellen Eisenberg; Hiroshi Nakagawa; Carmen Z Michaylira; Anil K Rustgi; Sanjay M Mallya
Journal:  Mol Carcinog       Date:  2009-09       Impact factor: 4.784

Review 3.  Molecular changes in the multistage pathogenesis of head and neck cancer.

Authors:  Brian J Park; Simion I Chiosea; Jennifer R Grandis
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

4.  The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway.

Authors:  M Carla Cabrera; Edgar S Díaz-Cruz; Bhaskar V S Kallakury; Michael J Pishvaian; Clinton J Grubbs; Donald D Muccio; Priscilla A Furth
Journal:  Cancer Prev Res (Phila)       Date:  2012-04-16

5.  Molecular biology of oral cavity squamous cell carcinoma.

Authors:  Phillip J Hsu; Kenneth Yan; Hailing Shi; Evgeny Izumchenko; Nishant Agrawal
Journal:  Oral Oncol       Date:  2020-01-07       Impact factor: 5.337

6.  Differences in the expression of five senescence markers in oral cancer, oral leukoplakia and control samples in humans.

Authors:  Antonio Bascones-Martínez; Mercedes López-Durán; Jorge Cano-Sánchez; Lydia Sánchez-Verde; Ana Díez-Rodríguez; Pablo Aguirre-Echebarría; Emilio Alvarez-Fernández; Miguel Angel González-Moles; Jaime Bascones-Ilundain; Lorenzo Lo Muzio; Julián Campo-Trapero
Journal:  Oncol Lett       Date:  2012-03-19       Impact factor: 2.967

7.  Cigarette smoke condensate and dioxin suppress culture shock induced senescence in normal human oral keratinocytes.

Authors:  Li Zhang; Ran Wu; R W Cameron Dingle; C Gary Gairola; Joseph Valentino; Hollie I Swanson
Journal:  Oral Oncol       Date:  2006-10-25       Impact factor: 5.337

8.  Effects of 1,4-phenylenebis(methylene)selenocyanate on mutagenesis and p53 protein expression in the tongue of lacI rats treated with 4-nitroquinoline-N-oxide.

Authors:  Joseph Guttenplan; Kun-Ming Chen; Michael Khmelnitsky; Wieslawa Kosinska; Jeannie Hennessy; Richard Bruggeman; Dhimant Desai; Shantu Amin; Yuan-Wan Sun; Tomas E Spratt; Karam El-Bayoumy
Journal:  Mutat Res       Date:  2007-07-17       Impact factor: 2.433

Review 9.  Molecular and cellular processes underlying the hallmarks of head and neck cancer.

Authors:  Jonathan M Bernstein; Clare R Bernstein; Catharine M L West; Jarrod J Homer
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-12-23       Impact factor: 2.503

10.  Overexpression of cell cycle regulator CDCA3 promotes oral cancer progression by enhancing cell proliferation with prevention of G1 phase arrest.

Authors:  Fumihiko Uchida; Katsuhiro Uzawa; Atsushi Kasamatsu; Hiroaki Takatori; Yosuke Sakamoto; Katsunori Ogawara; Masashi Shiiba; Hideki Tanzawa; Hiroki Bukawa
Journal:  BMC Cancer       Date:  2012-07-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.